I bought into RVX in September 2012 after seeing this Nature blog highlighting the success of the Sustain Trial. I'm a scientist, trained in studying metabolic diseases including obesity, fatty liver, insulin resistance and obtained my doctorate studying aspect of HDL and LDL metabolism. So investing in RVX was initially a high-risk, high-reward adventure. Its novel mechanism of action (most advanced BET bromodomain inhibitor drug in clinical trials) and ability to raise HDL (only other hope in trials now to raise HDL are CETP inhibitors) presented a huge opportunity to tacked the low-HDL population at risk for cardiovascular diseases. But now with what we know from the ASSURE/SUSTAIN post-hoc analysis, I am even more confident in RVX-208! GLTA, BDAZ